Articles tagged with Prostate Cancer
A new ultrasound technique called MRI-guided focused ultrasound ablation (MRgFUS) effectively treats intermediate-risk prostate cancer with minimal side effects. Treatment was successfully completed in all 44 men, with no major adverse events and 93% disease-free at the treatment site.
A team of researchers developed an AI analysis method to diagnose prostate cancer from urine within twenty minutes with almost 100% accuracy. The technique utilizes multiple cancer factors in urine to enhance diagnostic accuracy innovatively.
Scientists at Thomas Jefferson University discovered that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair mechanisms. The study found that CRY-1 is strongly associated with poor outcomes in late-stage prostate cancers.
A pooled data analysis suggests that drinking several cups of coffee daily may be associated with a lower risk of developing prostate cancer. The study found that each additional daily cup was linked to a relative risk reduction of nearly 1%, with the highest intake group showing a 9% lower risk compared to the lowest.
A study by researchers at UCLA Jonsson Comprehensive Cancer Center found that MRI frequently underestimates the size of prostate tumors, which can lead to undertreatment. The accuracy of treatment depends on precise measurements of both tumor size and PI-RADS score.
A new study found that a Mediterranean-style diet may help slow the progression of prostate cancer in men who are not seeking immediate treatment. Men with localized prostate cancer who followed a more plant-based diet had a lower risk of cancer growth or advancement, regardless of their age, PSA levels, or tumor volume.
Australian researchers have discovered a new mechanism by which prostate cancer cells can adapt and evolve into more aggressive forms, making them resistant to treatment. The study highlights the importance of targeting microRNA-194 to slow down and inhibit the growth of prostate cancer models with neuroendocrine features.
A large-scale genetic analysis of over 200,000 men from diverse backgrounds identified 86 new risk factors for prostate cancer. The study found significant disparities in risk between racial and ethnic groups, with African American men inheriting twice the risk of European American counterparts.
Researchers found that blocking the androgen receptor reduces coronavirus infection in mice and cellular models. Anti-androgen treatments are already FDA-approved, opening up potential COVID-19 treatment options.
Researchers identified genomic heterogeneity and immune content scores that predict lethal outcomes in grade 4/5 prostate cancer patients. The study found that approximately 25% of these patients were more likely to benefit from targeted treatment strategies.
Researchers investigated delaying radical prostatectomy surgery for up to six months in patients with high-risk prostate cancer. The results indicate that delaying surgery may be associated with worse outcomes, highlighting the need for personalized treatment decisions.
The new PSMA PET imaging technique has been shown to detect significantly more prostate lesions than current standard-of-care techniques. This breakthrough could lead to better treatment outcomes and more precise care for men with prostate cancer.
Researchers found that providing genetic feedback to high-risk individuals improves their understanding and perceived value of the information. The study aims to improve healthcare by enabling personalized prevention plans and treatments for people with hereditary predispositions.
A study of 514 men undergoing active surveillance for early-stage prostate cancer found that those with negative biopsies had more favorable clinical characteristics and excellent long-term outcomes. Negative biopsies indicated low-volume disease with lower rates of disease progression, supporting continued active surveillance.
Researchers identified a genetic signature in localized prostate cancer that can predict metastasis and treatment response. The signature, called META-16, was highly effective at predicting time to metastasis and response to anti-androgen therapy.
A recent study found that men undergoing active surveillance for low-risk and intermediate-risk prostate cancer have very low rates of cancer spread and death from prostate cancer. The study analyzed 1,450 patients and identified three factors that affect the risk of metastases: Gleason grade, PSA velocity, and multiparametric MRI.
African American men with low-risk prostate cancer treated under active surveillance have a higher risk of disease progression and mortality compared to non-African American patients. The study's findings suggest that racial disparities exist in the clinical outcomes of prostate cancer treatment with active surveillance.
African American men with low-risk prostate cancer can safely undergo active surveillance without increased risk of disease progression, metastasis, or death. The study found that African Americans experienced higher rates of disease progression and treatment compared to white men, but comparable mortality rates.
The study found that 5-year freedom from biochemical failure stands at 68%, comparable to other salvage modalities. At 10 years, the rate dropped to 54%. Late Grade 3 gastrointestinal and genitourinary adverse events occurred in 14% of participants.
Research reveals that African American men's prostate cancer tumors have higher frequencies of certain genetic alterations compared to white men. These alterations may contribute to more aggressive disease and higher mortality rates among Black men.
Researchers found that fluorine-18-labeled fluciclovine PET/MRI accurately identified prostate cancer lesions, suspicious lymph nodes, and detected nodal metastases not visible on conventional imaging. The technology also showed promise in evaluating response to androgen deprivation therapy.
A new study found that adding advanced PET scans to radiation plans for prostate cancer increases disease-free survival rates. After three years, 75.5% of patients treated with the additional imaging were still cancer-free, compared to 63% in the control group.
The study found that MFS was strongly correlated with OS (τ = 0.86), while BF and DM were only moderately and weakly correlated with OS, respectively. The analysis suggests that researchers should be cautious when inferring clinical benefit from studies using biochemical failure as a surrogate for overall survival.
A Winship Cancer Institute study shows that advanced molecular imaging with fluciclovine improves disease-free survival rates for patients with recurring prostate cancer after prostatectomy. The trial found a 12% better cancer control rate at three years, persisting at four years.
A new staging system called STAR-CAP has been developed to predict outcomes and inform treatment decisions for men with non-metastatic prostate cancer. The system, which uses patient, tumor, and outcome data from nearly 20,000 patients, has been validated and shows strong prognostic power.
African American men are more susceptible to prostate cancer due to immune-oncologic differences, which can be exploited for personalized treatment options. The study found elevated immune pathways and higher expression of T lymphocytes in African American prostate tumors, suggesting better responses to radiotherapy and immunotherapy.
Rutgers researchers identified 16 gene markers that collaborate to cause metastatic prostate cancer, enabling the prediction of high-risk patients. These markers can help inform personalized therapy and improve outcomes for those with advanced disease.
A study by Tampere University and the University of Oxford has identified a principle that explains how prostate cancer spreads, with implications for liquid biopsy. Researchers discovered that not all subclones spread to the entire body, and some may be confined to the prostate.
A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy by detecting prostate cancer tissue at the resection margin. CLI has shown high diagnostic accuracy in detecting tumor cells and positive surgical margins.
Researchers at Kanazawa University discovered that thymoquinone selectively kills prostate cancer cells with a SUCLA2 gene deletion. This finding offers a promising therapeutic option for advanced prostate cancer patients who have developed resistance to hormone therapy.
The availability of mpMRIp in Australia has led to a significant reduction in prostate biopsies by an average of 354.7 per month. This is estimated to save $13.2 million annually, making it a financially sensible policy from a healthcare perspective.
A phase 3 clinical trial found that ipilimumab improved progression-free survival by two to three times in patients with metastasized, castration-resistant prostate cancer. The treatment also showed overall survival benefits compared to the placebo arm.
Cryoablation, a less-invasive treatment technique, offers a promising alternative to surgery for prostate cancer control. According to the study, cryoablation provided a high rate of effective prostate cancer control in 82% of patients at 18-month follow-up.
A major trial shows olaparib, a PARP inhibitor, is more effective than modern hormone treatments in slowing down prostate cancer growth and spread. Patients with genetic alterations in DNA repair genes who received olaparib had a median overall survival of 19.1 months.
The PROfound trial demonstrates the efficacy of PARP inhibitor olaparib in treating metastatic castration-resistant prostate cancer (mCRPC) with at least one alteration in BRCA1 or BRCA2 genes. Olaparib significantly improves overall survival, particularly in patients with alterations in these genes.
A new study suggests that focal high-intensity focused ultrasound (HIFU) ablation is an effective alternative to surgery or radiation for treating prostate cancer. The procedure carries a low risk of complication and helps preserve quality of life, with no significant decrease in sexual function or urinary incontinence.
A study published in Cancer highlights racial disparities in prostate cancer deaths, with Black men facing a higher risk of death compared to white men. The analysis found that socioeconomic factors, such as education and median household income, contributed significantly to these disparities.
A new US study finds that HIFU provides adequate control of prostate cancer while avoiding significant side effects, with nearly 90% of men able to avoid or delay radical treatment. The non-invasive therapy also preserves sexual function and urinary symptoms, with no serious complications reported.
A new study by Umeå University researchers sheds light on the molecular mechanisms of prostate cancer cell mobilization. They found that an amino acid in TGF-β signalling molecule Smad7 enables cancer cells to spread and form life-threatening metastases.
A study of over 200,000 UK men found a link between central adiposity and the risk of death from prostate cancer. Those with larger waist circumferences were more likely to die from prostate cancer than those with smaller waist sizes.
A new device developed by Dartmouth engineers has the potential to improve patient outcomes for prostate cancer patients who undergo radical prostatectomy. The device, which uses microendoscopic electrical impedance sensing probe technology, aims to detect positive surgical margins and prevent disease recurrence.
A targeted therapy called rucaparib has been successfully used to treat men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes. The treatment resulted in a 41% objective response rate and improvements in prostate-specific antigen levels for over half of the patients.
A new study by Brigham and Women's Hospital found that delaying radiation therapy for men with unfavorable intermediate-risk or high-risk localized prostate cancer, who are receiving radiation and hormone therapy, is unlikely to impact survival. This flexibility in radiation timing could help patients minimize exposure to COVID-19 by s...
A study examined the association between radiotherapy timing and overall survival in patients with prostate cancer. The analysis of National Cancer Database data found that delaying radiotherapy relative to androgen deprivation therapy was associated with improved overall survival.
A new study found that acute exercise maintains the immune system's natural killer cell count at a normal level in prostate cancer survivors. Exercise appears to be safe and beneficial for these individuals, with no significant alterations in immune cell mobilization during treatment.
A recent study found an association between a healthy diet and reduced prostate cancer risk, as well as an increased risk with diets rich in sweets and beverages. The research team analyzed data from over 1,000 participants and identified key dietary patterns that may inform prevention strategies for prostate cancer.
A study published in The Lancet Digital Health demonstrates an AI program's highest accuracy to date in recognizing and characterizing prostate cancer. The algorithm achieved 98% sensitivity and 97% specificity in detecting prostate cancer, surpassing previously reported results.
A genomic signature associates with differential expression of glucose transporters and hexokinase proteins in prostate cancers with low PSMA expression. This allows for improved uptake of 18F-FDG compared to PSMA-targeted radioligands, making it an attractive imaging tool for neuroendocrine prostate cancer patients.
BRD4 protein regulates key proteins contributing to prostate cancer progression, suggesting new therapeutic target. Current treatments for castration-resistant prostate cancer are limited and focus on suppressing tumor cells' reliance on androgen receptor signaling.
A study published in Nature Genetics confirms decades-old hypothesis that metastatic disease hijacks tissue-specific developmental programs. The researchers analyzed epigenetic data from patient-derived samples and identified thousands of sites across the prostate genome regulating gene expression.
A global methodology has been developed to help decide when to treat prostate cancer, providing a single standard for estimating tumour aggressiveness. The GAP3 consortium's analysis of 14,380 patients reveals that certain factors can predict cancer development, enabling more informed treatment decisions.
A major study conducted by patients themselves reports significant numbers struggling with continence and sexual problems after prostate cancer treatment. The Europa Uomo Patient Reported Outcomes Study found that any treatment apart from active surveillance negatively affects quality of life.
Researchers found the AZIN1 gene associated with metastatic prostate cancer, with reduced expression leading to fewer metastases. Further investigation is needed to confirm findings in all prostate cancers.
Researchers at Baylor College of Medicine have discovered a new site on the androgen receptor that interacts with activity-enhancing coactivators, driving prostate cancer growth. The study's findings provide insights into the design of future treatments for this devastating condition.
Researchers developed a novel radioiodinated PSMA-targeting radiopharmaceutical that can be produced in high yields without generating volatile byproducts. The agent shows exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies, targeting prostate-specific membrane antigen (PSMA).
A multicenter trial found that PSMA PET/CT identified disease in over half of patients with negative conventional imaging, leading to changes in management in 66% of cases. The most common changes were conversion to surgery or radiation, or addition of nodal-directed therapy.
A literature review found significant evidence supporting the causal role of high-risk HPV types 16 and 18 in prostate cancer. The authors suggest that HPV vaccination may help prevent prostate cancer development, particularly in countries with high mortality rates from cervical cancer.
A new study has identified genes more frequently altered in prostate tumors from men of African ancestry compared to other racial groups. The research found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, but suggests that precision medicine approaches can be effective if...
Researchers used ChIA-PET to map associations between proteins and DNA in prostate cancer cells, discovering hubs of interacting enhancers that regulate gene expression. These findings may lead to novel treatments for the most common type of prostate cancer.
A recent study published in Radiology found that prostate MRI quality is highly variable across institutions, with a significant impact on cancer detection and treatment outcomes. The study's findings suggest that improved standardization and training are needed to ensure consistent imaging results and better patient care.